Validation of a Risk Score Opportunistic Infections Development in Kidney Transplant Patients

NCT03083756 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 577

Last updated 2017-03-20

No results posted yet for this study

Summary

This study validate the usefulness of SIMPLICITY score to characterize the immune status of the kidney transplant receiver at two points along its course (the one and six months after transplantation), by determination in peripheral blood of various parameters related to cellular immunity (count subpopulations of CD3+ (cluster of differentiation 3), CD4+ (cluster of differentiation 4) and CD8+( cluster of differentiation 8)), humoral immunity (immunoglobulins count) and innate (complement).

Conditions

  • Opportunistic Infections

Sponsors & Collaborators

  • Roche Farma, S.A

    collaborator INDUSTRY
  • Sociedad Española de Trasplante

    lead OTHER

Principal Investigators

  • José María Aguado, MD · Hospital Universitario 12 de Octubre

  • Daniel Serón, MD · Hospital Universitario Vall d´Hebrón

  • Ángel Alonso, MD · Hospital Universitario de A Coruña

  • Domingo Hernández Marrero, MD · Hospital Carlos Haya

  • Álex Gutiérrez Dalmau, MD · Hospital Miguel Servet

  • Roberto Gallego, MD · Hospital Dr. Negrín

  • Juan Carlos Ruiz, MD · Hospital Marqués de Valdecilla

  • Frederic Cofàn, MD · Hospital Clinic of Barcelona

  • José M Cruzado, MD · Hospital Universitari de Bellvitge

  • Daniel Serón, MD · Hospital Universitario Vall d´Hebrón

  • María José Pérez Sáez, MD · Hospital del Mar

  • Miguel Angel Muñoz Cepeda, MD · Hospital Virgen de la Salud

  • Ángel Alonso, MD · Hospital Universitario de A Coruña

  • Gonzalo Gómez, MD · Hospital Son Espases

  • Amado Andrés, MD · Hospital Universitario 12 de Octubre

  • José Mª Portolés, MD · Hospital Universitario Puerta de Hierro Majadahonda

  • Roberto Marcén, MD · Hospital Universitario Ramon y Cajal

  • Luisa Jimeno Garcia, MD · Hospital Virgen de la Arrixaca

  • Luis M Pallardó Mateu, MD · Hospital Dr. Peset

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-02-15
Completion
2017-02-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03083756 on ClinicalTrials.gov